AstraZeneca received approval from the U.S. Federal Trade Commission to buy the pharmaceutical company Alexion Pharmaceuticals. The company only needs to get approval of the deal from regulators in the UK, EU and Japan. The purchase will cost AstraZeneca $39 billion, or $175 per share. Alexion shareholders will receive $60 and 2.1243 ADRs of AstraZeneca for each of their shares. The transaction is expected to close in Q3 2021. Following the merger, Alexion shareholders will own 15% of the combined company.
AstraZeneca received approval from the U.S. Federal Trade Commission to buy the pharmaceutical company Alexion Pharmaceuticals. The company only needs to get approval of the deal from regulators in the UK, EU and Japan. The purchase will cost AstraZeneca $39 billion, or $175 per share. Alexion shareholders will receive $60 and 2.1243 ADRs of AstraZeneca for each of their shares. The transaction is expected to close in Q3 2021. Following the merger, Alexion shareholders will own 15% of the combined company. 
astrazeneca.com
English (US) 